Janux Stock Launches 230% On Its'Significant Opportunity' In Prostate Cancer Treatment
(Source: Reuters: Health)
Source: Reuters: Health - February 28, 2024 Category: Consumer Health News Source Type: news
Janux Stock Launches 180% On Its'Significant Opportunity' In Prostate Cancer Treatment
Janux Therapeutics unveiled promising results for a prostate cancer treatment on Tuesday, and the biotech stock nearly tripled. The post Janux Stock Launches 180% On Its 'Significant Opportunity' In Prostate Cancer Treatment appeared first on Investor's Business Daily.#januxtherapeutics #januxstocklaunches (Source: Reuters: Health)
Source: Reuters: Health - February 27, 2024 Category: Consumer Health News Source Type: news
Risk of fractures and falls in men with advanced or metastatic prostate cancer receiving androgen deprivation therapy and treated with novel androgen receptor signalling inhibitors: a systematic review and meta-analysis of randomised controlled trials - Jones C, Gray S, Brown M, Brown J, McCloskey E, Rai BP, Clarke N, Sachdeva A.
CONTEXT: The addition of androgen receptor signalling inhibitors (ARSIs) to standard androgen deprivation therapy (ADT) has improved survival outcomes in patients with advanced prostate cancer (PCa). Advanced PCa patients have a higher incidence of osteopo... (Source: SafetyLit)
Source: SafetyLit - February 26, 2024 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
A&E doctor shares six signs of prostate cancer as 'diagnoses are increasing'
If you spot any of these signs you should speak to your GP. (Source: Daily Express - Health)
Source: Daily Express - Health - February 24, 2024 Category: Consumer Health News Source Type: news
Cancer incidence during pandemic lower than expected
Overall cancer incidence in the U.S. was significantly lower than expected during the first 10 months of the COVID-19 pandemic, according to research published February 22 in JAMA Oncology.
A team led by Krystle Lang Kuhs, PhD, from the University of Kentucky in Lexington found that cancer incidence from March to December 2020 included 134,395 potentially undiagnosed cancer cases, lower than expected.
“These findings identify a substantial deficit of diagnosed cancer cases in the U.S. during the COVID-19 pandemic in 2020, which underscores the need to reengage individuals in recommended cancer screenings and routine he...
Source: AuntMinnie.com Headlines - February 22, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Subspecialties CT Breast Imaging Source Type: news
Cabozantinib Plus Atezolizumab Improves PFS in Metastatic CRPC
(MedPage Today) -- In patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed on a novel hormonal therapy, the combination of cabozantinib (Cabometyx) plus atezolizumab (Tecentriq) improved radiographic progression... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 22, 2024 Category: Hematology Source Type: news
Perceived vs Actual Cognitive Impairment in Prostate Cancer Perceived vs Actual Cognitive Impairment in Prostate Cancer
Following hormone therapy, patients with prostate cancer may perceive an increase in cognitive issues, despite tests showing no objective decline, a recent meta-analysis found.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 22, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Is MRI Screening Unnecessarily High in Prostate Cancer? Is MRI Screening Unnecessarily High in Prostate Cancer?
New research suggests that review of current prostate cancer screening guidelines may be needed, as MRI frequently fails to detect cancer-indicative lesions, even in men with elevated PSA levels.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 21, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Nigeria: Prostate Cancer - Medicaid Cancer Foundation Partners Raise Awareness Using Art
[Daily Trust] Medicaid Cancer Foundation (MCF) and partners have said art plays a critical role in the fight against prostate and other types of cancer. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 21, 2024 Category: African Health Tags: Health and Medicine Nigeria West Africa Source Type: news
Stephen Fry slams 'deadly' waits for NHS cancer treatment and urges ministers to get a grip on crisis after his own prostate cancer battle
Throwing his support behind the #CatchUpWithCancer campaign, Stephen Fry slammed the 'deadly' delays tens of thousands have faced. (Source: the Mail online | Health)
Source: the Mail online | Health - February 20, 2024 Category: Consumer Health News Source Type: news
Blue Earth highlights early lutetium-177 prostate cancer clinical results
Blue Earth Therapeutics is highlighting early clinical results from a German trial investigating the use of a lutetium-177 (Lu-177)-labeled prostate specific antigen (PSMA) radiopharmaceutical.
A study conducted by researchers from University Hospital Augsburg in Germany used Blue Earth's Lu-177-labeled radiohybrid (rh) prostate-specific membrane antigen (Lu-177 rhPSMA-10.1) and its findings were published in December in the Journal of Nuclear Medicine.
The German team reported that of four patients with metastatic prostate cancer who were assessed for radiologic progression-free survival, two had not progressed at 24 an...
Source: AuntMinnie.com Headlines - February 20, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Focal Therapy for Prostate Cancer: Is It Being Oversold? Focal Therapy for Prostate Cancer: Is It Being Oversold?
Despite growing enthusiasm for this minimally invasive option for some men with prostate cancer, focal therapy is still not FDA-approved for prostate cancer and comes with high out-of-pocket costs.Medscape Medical News (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - February 20, 2024 Category: Urology & Nephrology Tags: Hematology-Oncology Source Type: news
Radioligand Therapy Continues to Show Promise for Metastatic CRPC
(MedPage Today) -- Radioligand therapy (RLT) with actinium-225 targeting prostate-specific membrane antigen (225Ac-PSMA) had a "substantial antitumor effect" in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC), a large... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 17, 2024 Category: Hematology Source Type: news
More Data Support Olaparib-Abiraterone in BRCA-Mutant Prostate Cancer
(MedPage Today) -- Combining olaparib (Lynparza) with abiraterone acetate (Zytiga) as first-line therapy for biomarker-selected patients with metastatic castration-resistant prostate cancer significantly improved progression-free survival (PFS... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 15, 2024 Category: Hematology Source Type: news
Toppling the Genetic Dominoes in Bone Metastasis
A key gene that fuels the molecular cascade driving prostate cancer bone metastasis progression may open avenues for targeted therapies. (Source: The Scientist)
Source: The Scientist - February 15, 2024 Category: Science Tags: News News & Opinion Source Type: news
